Skip to main content
SpringerLink
Log in

Rate control in atrial fibrillation, insight into the RACE II study

  • ICIN
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.

    Article  Google Scholar 

  2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.

    Article  Google Scholar 

  3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.

    Article  CAS  Google Scholar 

  4. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.

    Article  CAS  Google Scholar 

  5. Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765–9.

    Article  CAS  Google Scholar 

  6. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695–703.

    Article  CAS  Google Scholar 

  7. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303–9.

    Article  CAS  Google Scholar 

  8. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2004;43:241–7.

    Article  Google Scholar 

  9. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA. 1962;182:548–55.

    Article  CAS  Google Scholar 

  10. Brown KW, Whitehead EH, Morrow JD. Treatment of cardiac arrhythmias with synchronized electrical countershock. Can Med Assoc J. 1964;90:103–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. McDonald L, Resnekov L, O’Brien K. Direct-current shock in treatment of drug-resistant cardiac arrhythmias. Br Med J. 1964;1:1468–70.

    Article  CAS  Google Scholar 

  12. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–94.

    Article  CAS  Google Scholar 

  13. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.

    Article  CAS  Google Scholar 

  14. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.

    Article  Google Scholar 

  15. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–6.

    Article  Google Scholar 

  16. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004;126:476–86.

    Article  Google Scholar 

  17. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM study. Circ J. 2009;73:242–8.

    Article  Google Scholar 

  18. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.

    Article  CAS  Google Scholar 

  19. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.

    Article  Google Scholar 

  20. Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] study). Am J Cardiol. 2004;93:1247–53.

    Article  Google Scholar 

  21. Groenveld HF, Crijns HJ, Rienstra M, et al. Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. Am Heart J. 2009;158:785–91.

    Article  Google Scholar 

  22. Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest. 1977;71:592–6.

    Article  CAS  Google Scholar 

  23. David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378–82.

    Article  CAS  Google Scholar 

  24. Stern EH, Pitchon R, King BD, et al. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest. 1982;81:308–11.

    Article  CAS  Google Scholar 

  25. Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest. 1983;83:491–9.

    Article  CAS  Google Scholar 

  26. Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol. 1983;52:1197–201.

    Article  CAS  Google Scholar 

  27. DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121–7.

    Article  CAS  Google Scholar 

  28. Myers J, Atwood JE, Sullivan M, et al. Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation. J Appl Physiol. 1987;63:97–104.

    Article  CAS  Google Scholar 

  29. Atwood JE, Myers JN, Sullivan MJ, et al. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest. 1988;93:20–5.

    Article  CAS  Google Scholar 

  30. Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167–74.

    Article  CAS  Google Scholar 

  31. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol. 1995;75:88–90.

    Article  CAS  Google Scholar 

  32. Atwood JE, Myers J, Quaglietti S, et al. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest. 1999;115:1175–80.

    Article  CAS  Google Scholar 

  33. Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–10.

    Article  CAS  Google Scholar 

  34. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201–8.

    Article  Google Scholar 

  35. Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8:935–42.

    Article  Google Scholar 

  36. Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152:420–6.

    Article  Google Scholar 

  37. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.

    Article  Google Scholar 

  38. Groenveld HF, Tijssen JG, Crijns HJ, et al. Rate Control Efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control. Data from the RACE II study. J Am Coll Cardiol. 2013;61:741–8.

    Article  Google Scholar 

  39. Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace. 2011;13:626–33.

    Article  Google Scholar 

  40. Nieuwlaat R. The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research. Europace. 2011;13:601–2.

    Article  Google Scholar 

  41. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103:1428–33.

    Article  CAS  Google Scholar 

  42. Van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail. 2006;8:539–46.

    Article  Google Scholar 

  43. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–76.

    Article  CAS  Google Scholar 

  44. Groenveld HF, Crijns HJ, Van den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58:1795–803.

    Article  Google Scholar 

Download references

Funding

The study was funded by a major grant obtained from the Netherlands Heart Foundation and unrestricted educational grants from AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic, Roche and Sanofi Aventis France paid to the Interuniversity Cardiology Institute Netherlands.

Conflict of interest

Dr. Van Gelder reports receiving consulting fees from Sanofi-Aventis, Boehringer Ingelheim and Cardiome, grant support from Medtronic, Biotronik and St. Jude Medical, lecture fees from Sanofi-Aventis, Boehringer Ingelheim and Medtronic. Dr. Crijns reports receiving consulting fees from Boehringer Ingelheim, Sanofi-Aventis and AstraZeneca, grant support from St. Jude Medical, Boston Scientific, Boehringer-Ingelheim, Sanofi-Aventis, Medapharma and Merck, and honoraria from Medtronic, Sanofi-Aventis, Medapharma, Merck, Boehringer-Ingelheim and Biosense Webster, Dr. Alings reports receiving consulting fees from Bayer-AG, BMS-Pfizer and Boehringer Ingelheim, Dr. Van Veldhuisen reports having received Board memberships from Amgen, BG Medicine, Johnson & Johnson, Sorbent, Novartis, and Vifor.

Author information

Authors and Affiliations

  1. Department of Cardiology, Thoraxcenter, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, the Netherlands

    H. F. Groenveld, M. P. Van den Berg, D. J. Van Veldhuisen & I. C. Van Gelder

  2. Maastricht University Medical Center, Maastricht, the Netherlands

    H. J. G. M. Crijns

  3. University of Amsterdam, Amsterdam, the Netherlands

    J. G. P. Tijssen

  4. Interuniversity Cardiology Institute Netherlands, Utrecht, the Netherlands

    J. G. P. Tijssen & I. C. Van Gelder

  5. Amphia Hospital, Breda, the Netherlands

    M. Alings

  6. Trial Coordination Center, Department of Epidemiology, University Medical Center Groningen, Groningen, the Netherlands

    H. L. Hillege

  7. Deventer Hospital, Deventer, the Netherlands

    Y. S. Tuininga

Authors
  1. H. F. Groenveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. J. G. M. Crijns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. G. P. Tijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Alings
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. L. Hillege
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. S. Tuininga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. P. Van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. J. Van Veldhuisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. C. Van Gelder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. C. Van Gelder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Groenveld, H.F., Crijns, H.J.G.M., Tijssen, J.G.P. et al. Rate control in atrial fibrillation, insight into the RACE II study. Neth Heart J 21, 199–204 (2013). https://doi.org/10.1007/s12471-013-0391-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12471-013-0391-1

Search

Navigation